Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

ONCS
OncoSec Medical Inc
stock NASDAQ

At Close
3/29/2023 3:59:30 PM EDT
2.24USD-0.885%(-0.02)278,994
2.22Bid   2.70Ask   0.48Spread IEX
Pre-market
3/29/2023 9:08:36 AM EDT
2.44USD+7.965%(+0.18)1
After-hours
3/27/2023 4:01:30 PM EDT
2.71USD+3.038%(+0.08)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
6.656M
CEO
Daniel O'Connor
Headquarters
Pennington, New Jersey, USA
Industry
Biotechnology
Next Earnings
2023-06-14 (77d)
Last Split
2022-11-091for22reverse
Related
IMMUCASSZIOPINOEIGRXLV
ONCS Stats
Avg. Vol. 10 Day
564,925
Avg. Vol. 30 Day
5,858,632
Employees
40
Market Cap
6,655,591
Shares Out.
2,971,246
Float
2,051,735
On/Off Exchange
55%/45%
6 Month Beta
-0.22
1 Year Beta
0.28
2 Year Beta
0.52
3 Year Beta
0.34
52 Week Low
0.74
52 Week High
31.90
SMA50
1.86
SMA200
4.76
1 Week
+16.06%
1 Month
+9.80%
3 Month
+20.43%
6 Month
-79.22%
1 Year
-91.59%
2 Year
-97.90%
5 Year
-99.46%
Dec 17, 2021
09:10AM EST  OncoSec Announces Changes to its Board of Directors   PR Newswire
Dec 7, 2021
08:26AM EST  The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Dar   Benzinga
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Nov 12, 2021
07:47AM EST  The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares   Benzinga
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
More News
Profile
OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions.

ONCS Stock Summary

OncoSec Medical Inc (NASDAQ:ONCS) stock price today is $2.24, and today's volume is 278,994. ONCS is down -0.885% today. The 30 day average volume is 5,858,632. ONCS market cap is 6.656M with 2,971,246 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC